PRPO

Welcome to the Precipio first quarter 2026 shareholder update conference call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts, and assumptions and are subject to significant risk and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms, other words or terms of similar meaning.

Risk and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under risk factors in our annual report on Form 10-K for the year ended December 31st, 2025, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward-looking statements, speak only to the date they are provided, unless an earlier date is indicated. We do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Now, let me hand the call over to Ilan Danieli, Precipio CEO.

Good afternoon, everyone, thank you for joining us today for Precipio's Q1 2026 shareholder update call. On today's call, we'll walk through our financial results, provide an update on our operations and commercial progress, and then for the first time, in following requests from several of our shareholders, we're gonna open it up for live Q&A from the audience. At the end of my remarks, the operator is gonna take over and provide instructions for those who wanna ask a question. Before reviewing the quarterly financials for Q1, I'd like to take a moment to step back and discuss where we believe the company is in the execution of its strategy. Our mission at Precipio is centered around advancing cancer diagnostics by delivering faster, more accessible and more actionable testing solutions to laboratories and clinicians.

What makes our model unique is that we're not only developing products in isolation. By operating our own clinical laboratory, we identify real-world diagnostic challenges firsthand, validate solutions rapidly in a clinical environment, and then once our products have demonstrated their clinical, operational and financial value, we commercialize them to the broader market. Over the past several quarters, we've continued to strengthen both sides of that model. Our pathology business continues to provide a stable and growing operational foundation while generating cash flow to the company. Our products business and expanding commercial infrastructure are positioning the company for scalable long-term growth, margin increase, and cash generation. Before we get to the numbers, I'd like to take a moment to discuss a topic that several people have raised and that is the variability and predictability of the company's revenues.

Let's break it down by division, starting with pathology services. Generally speaking, the pathology services business is relatively predictable. Once we win a customer, they usually have a consistent number of patients coming in. There's a relatively consistent percent of those patients that will require some sort of biopsy, which is sent to our lab. Testing modalities are pretty standard. We control costs extremely well, so there isn't much variance there. The same goes for revenue build, reimbursement, and cash collected, all quite predictable. There are two elements that are outside of our control and can cause fluctuations in the division performance. The first is customer transition. For example, a physician may retire or their practice may get acquired by a large hospital network that internalizes testing. In those situations, the patient sample flow from that customer will stop.

The second element, which we experienced this quarter, is a change to reimbursement. Each year, usually in January, CMS comes out with its new fee schedule. As a government organization, there's no negotiations, the new fee schedule basically becomes our new pricing. As you can imagine, there are very few rate increases and usually it goes the other way. In early Q1 of this year, the new 2026 CMS fee schedule was released and it included a reduction of 8% in the fee for one of our most frequently used tests, flow cytometry. Subsequently, we had to write down revenue this quarter to the tune of approximately half a million dollars, creating a significant swing in net income from the prior quarter.

While there was no change to our customer base or patient sample volume, the new fee schedule introduced by CMS impacted our revenue, net income, and gross margins. We've been working on several projects to reduce our operating costs and bring back up that margin, essentially reversing the impact of the fee schedule. As you saw, our cash flow from operations was still positive. That essentially covers the drivers of variability in the pathology services business. On the product side, generally speaking, once a customer is live and operating, revenues are quite stable and predictable. This quarter, we saw an $80,000 decline in revenue from the prior quarter, and this was due to one of our main customers shifting the date of their order from the end of March to early April.

While nothing changed from a customer perspective, following the principles of revenue recognition, of course, this order will be part of Q2 revenue. This is one relatively small factor that can cause fluctuations within the product business. The second and more challenging variable is the onboarding process for customers. We've discussed this in the past and shared stories ranging from IT roadblocks to machine downtime during validations. I know many of you have inquired about guidance and forecasting, and I do think that as we grow the customer base and gain more experience, we will be able to better predict our future growth. Also, with a new commercial team building a broader pipeline, that will help us gain better insight into future growth as well. I'll add more on the pipeline later in this call.

Even within the product business, those fluctuations are mostly related to initial setup of the customer. Once the customer is live, there are far fewer fluctuations and revenue is more predictable. As we grow our customer base and get more experience under our belt, I do think we will eventually reach the point where we can begin to become more comfortable in predicting revenue growth. In summary, as with any business, we have to deal with fluctuations both internal, but in our situation, more from external factors that are largely outside of our control. However, they are more prevalent in the pathology services business than the product business, which is yet another reason why the product business is our growth focus. With that, let's turn to a review of our financial results for the quarter.

Total revenue for Q1 remained flat quarter-over-quarter at $6.71 million and up over 30% from the same quarter last year. Pathology revenue increased a little over $6 million this quarter from $5.9 million the previous quarter and up 36% from $4.4 million in Q1 of last year. Product revenue decreased by $80,000 from $740,000-$660,000 this quarter, impacted by the timing of a customer shipment originally expected later in the quarter that moved into Q2. From an accounting standpoint, that revenue shifts quarter, but from a business standpoint, nothing really has changed.

More importantly, the quarter reflects continued progress in areas we believe are the strongest indicators of future growth, particularly commercial expansion, distributor engagement, and pipeline development, marking a foundational quarter for our expanded commercial strategy. I'd like to take a few moments to discuss those results. As we've mentioned, we recently invested in hiring a dedicated commercial team focused on accelerating adoption of our proprietary product portfolio through distributor relationships and direct customer engagement. Given the onboarding and sales cycle associated with molecular diagnostic products, the team's initial focus has been on building relationships and educating our distribution partners, identifying qualified target accounts, and developing a scalable pipeline. This takes place via a process that begins primarily with our distributors.

As we've described in the past, our team has to first form relationships with the distributor reps and familiarize them with our company, with our value proposition, and with our product offering. Once that occurs, they can begin to review with each rep their territory and identify qualified potential leads. The way we qualify leads is through a pretty straightforward process. First, we ensure that the customer has existing cancer diagnostic operations and is either running some of the tests our products replace in-house or most likely sending them to an outside lab. This establishes the customer as an appropriate target lab. Once we've established that, we learn which products they're interested in and their annual volumes to assess and assign an estimated annual dollar revenue potential based on their existing testing volume for our panels.

With an annual revenue potential number, this account now becomes a qualified lead, we begin the work together with the distributor rep of arranging an introduction meeting to start the sales process. That work started with the hire of the commercial team at the start of the year and is already beginning to produce measurable results. During Q1, the commercial team established relationships with approximately 20 new distributor reps, identified two, sorry, 10 new qualified customer opportunities, and added approximately $3 million of annualized revenue potential to the pipeline. Combined with existing opportunities, our current commercial pipeline now represents approximately $10 million in annualized revenue potential. As a reminder, this does not translate into a forecast of $10 million for this year because the X factor we don't know is when each customer will go live.

We do feel that this represents a thorough and responsible process for targeting customers and generating a sales funnel and future pipeline. We believe this is particularly encouraging given that the sales team only joined at the start of the year and initially underwent extensive training on our technology, product portfolio, market dynamics, and competitive positioning. Many of these early results validate both the market opportunity as well as our commercial strategy. As the team continues expanding distributor relationships and converting qualified opportunities into active customers, we expect the pipeline to continue to grow as well as also increase converting into recurring revenue. Let's turn to profitability and margins. Adjusted EBITDA for the quarter was negative $200,000, compared with positive $960,000 in Q4 of 2025.

A relatively large swing I'd like to take a few moments to discuss. Importantly, the majority of that sequential change was driven by a combination of timing-related items, non-recurring accounting impacts, and investments we're making to support future growth. There were four primary factors impacting QoQ EBITDA change. First, as discussed, this quarter, we experienced a reimbursement-related impact tied to the change in certain CMS pathology billing codes, which reduced our gross profit by approximately $125,000. Second, the hiring of our commercial team resulted in an increase of approximately $250,000 for the quarter. This includes payroll, travel, and business development expenses, as well as marketing activities. As we shared, we've already seen commercial benefits from this hiring in terms of the pipeline growth.

Importantly, we view this not only as incremental overhead but as a strategic investment in building the commercial platform necessary to scale our products business over the coming years. In other words, once this team begins to generate increased revenue of, let's say, $1 million per quarter, the investment of a quarter million dollars per quarter will certainly have paid off. Third, in Q4 2025, we benefited from a one-time, non-recurring accounting adjustment related to previously accrued bonus compensation, which created an approximately $260,000 positive swing in adjusted EBITDA compared to the current quarter. Lastly, we saw a $280,000 reduction in product gross profit related to the delivery timing shift from late Q1 to early Q2 and reduced production volumes. From a business activity perspective, this revenue was not lost.

It simply moved across reporting periods. The combination of these factors caused a $1 million swing in EBITDA. As you can see, a significant dollar amount of these are one-time changes that are unrelated to the company operations. Moving now to discuss gross margins. Company gross margin for the quarter was 40% compared to 47% in Q4. As with EBITDA, we believe it's important to distinguish between structural margin pressure and temporary or investment-driven impacts. The margin compression this quarter was primarily associated with the same factors we just discussed. Revenue timing, reimbursement changes, and investments in commercial capacity that are now largely in place. Also, Q4 margins were somewhat inflated due to overproduction of products in Q4 relative to Q1 due to the expected equipment downtime for maintenance as we stated previously.

Resumption of regular production volume and continued growth will bring a return to higher margins, which are inherent in the underlying economics of this business. What gives us confidence going forward is that many of these costs are relatively fixed in nature. As revenue grows, particularly in the product segment, we believe the business has the potential to generate meaningful operational leverage. Overall, for the business, we would expect company margins to not only recover as product revenue scales but over time, potentially improve beyond historical levels as the revenue mix increasingly shifts to our proprietary products and product-driven services. Turning briefly to cash flow. Total cash flow for the quarter was negative approximately $40,000, while cash flow from operations remained positive at approximately $60,000.

This pattern is generally consistent with what we historically see in the first quarter of the year, driven primarily by the combination of start-of-the-year annual expense resets, along with slower collections associated with patient insurance deductible cycles. Importantly, we don't view the quarter's cash flow performance as a negative of any structural change in the business, but rather normal seasonality that we expect to normalize as the year progresses. Looking ahead, a couple of points I'd like to make. First, we expect continued expansion of our commercial pipeline and increased conversion of that pipeline into revenue during the second half of the year. Second, we expect margins to improve as recent commercial investments begin contributing more meaningfully to revenue growth, and we scale up production. Finally, overall, we expect stronger operational performance as we move through the balance of 2026.

While quarterly results may fluctuate at times due to reimbursement dynamics, shipment timing, or seasonality, we do believe the broader trajectory of the business remains very positive. We're continuing to grow our commercial reach, extend our pipeline, strengthen our product platform, and invest in the infrastructure we believe necessary to build a substantially larger and more scalable business over time. With that, I'm gonna hand it over to the operator to open up the call for questions. Operator, please go ahead. Thank you.

Thank you. Ladies and gentlemen, we will now begin the question-and-answer session. To join the question queue, you may press star then one on your touchtone phone. You will hear a tone acknowledging your request. If you're using a speakerphone, please pick up your handset before pressing any keys. To withdraw your question, please press star then the number 2. We'll pause for a moment to compile the Q&A roster.

Thank you, Chloe. Meanwhile, as we build this roster, there's a couple of questions that were sent in in advance of the call. I'm gonna go through those, and then we can go to the live Q&A. The first question was, can you elaborate on the utilization rate of your labs, or in other words, how much more revenue can your current laboratories generate without significant CapEx? We're currently operating pathology services business at approximately $24 million on an annualized basis. We believe that, but this depends on the case mix, we have between $45 million-$50 million in laboratory capacity before we need to make any changes that involve any significant CapEx or hiring.

Second question. In your recent corporate deck, there's a slide that mentions the expansion potential of your technology into broader multi-million dollar markets. Is there a specific roadmap for these expansion plans? If yes, how much additional CapEx and R&D expenses is foreseen with which kinds of financings? That's a really important question, and it really gets to the core of how we think about the long-term evolution of Precipio. Today, our primary focus remains execution within our existing product portfolio and the markets we already serve. Even within our current addressable market, we're still at the very early stages of market penetration. To put that in perspective, our products business generated just under $3 million in revenue last year, and this is within an annual TAM of about half a billion dollars in the U.S.

We see a very significant runway for growth with the products we already have in place. That said, one of the reasons we reference broader market opportunities in our corporate materials is because we believe the underlying platform we've built have applications well beyond our current hematology-focused offerings. What's unique about Precipio is not any single product, it's the model itself, the combination of a real-world clinical laboratory environment, proprietary diagnostic workflows, operational validation capabilities, and commercial distribution infrastructure. We believe that over time, this model can be applied to additional areas of diagnostics. Having said that, we intend to approach expansion in a disciplined manner. Our philosophy is to continue scaling the existing product business, expand recurring revenue, strengthen cash flow generation, and leverage the commercial infrastructure we're building today.

As the company grows and becomes increasingly well-capitalized, we believe we'll be in a strong position to selectively expand into adjacent markets without necessarily requiring the kind of large-scale R&D spending and associated capital typically associated with traditional diagnostic companies. I think that's a really important distinction because our development model is tightly integrated with our clinical operations, and we think we can potentially enter new markets with a lower development risk, shorter validation cycles, and significantly more capital efficiency than many traditional life sciences. In summary, while we're not announcing any specific expansion initiatives today, we do believe the long-term opportunity for the platform extends meaningfully before the markets we currently serve. All right. With that, Chloe, let's go to our first question.

We have a question from Adam Hutt from Leviticus Partners. Your line is open.

Hey, guys. Thank you. It's really just a continuation of what the questions you've kind of already answered, would you be likely at all to open up a, for instance, a facility in the Midwest or the West? Would the logistics preclude that, or is transportation so efficient that, you know, you'll never need another facility elsewhere?

Thanks, Adam. Hey, good to hear from you. Good question. I don't think so. Logistics are, for the most part, quite good, and there really isn't a significant need to spend that kind of money to duplicate the facility. I can tell you, for example, as you know, our lab is in Connecticut. Even from New Jersey, samples get picked up by FedEx, and they fly through Memphis and arrive the next morning at 9 or 10 in the morning. There really isn't much advantage, you know, even from an adjacent state, there isn't much logistic advantage to having something on the West Coast.

I think if anything, as we get to that point, you know, we'll expand capacity, which for a large part is mostly on the CapEx kind of equipment side and at those revenue levels, it's a very efficient process.

New Haven would expand. No Los Angeles facility. Okay.

No, no. There's no need for that.

Thank you.

You bet. All right. Chloe, it seems like that's the only question.

Yes, there are no questions at this time. Thank you for attending today's presentation. Oh, we have one from Thomas Duxbury. Your line is open.

Okay.

Hi, Ilan. Congrats on the continued ramping and cash flow management of the company. I guess could you give us a little bit more color on the ramp, especially on the product side from Q2 onward through the rest of the year? I assume with that order shipping in Q2 into April, that Q2 will obviously be up from Q1 and hopefully with the commercial team that you have now in place, that we will see an even better loaded back half of the year. Thank you.

Yeah. Hey, Tom. Good to hear from you. Yeah, I hope so too. I think, you know, the commercial team has probably had already a better than expected impact in Q1. As I mentioned, keep in mind, you know, they've only been those four months, I would say at least half of that time has been for training. To add about a $3 million of pipeline is great, I think that's only gonna increase over time. Of course, the X factor, you know, is how long does it take to translate that $3 million of pipeline into $3 million of revenue and this is where it gets really difficult because a lot of those factors are out of our control.

You know, as an example, we had a customer I just spoke with a customer this morning who has completed the validation and is ready to go live from a technical standpoint. What they're now waiting for is to set up a meeting with all the physicians to teach them how to order the new test of the system. It sounds mind-numbingly ridiculous, quite frankly, but those are the things we face. You know, this is a huge organization, so they have these meetings once a quarter, and that hasn't been scheduled yet. You know, this meeting could happen next week, and the customer goes live. This meeting could happen in July, and then the customer goes live.

It's really hard to kind of figure out what is the timeline for these customers to transition from readiness to go live and when that translates into revenue? I think, you know, the best thing I can offer is sufficient. If the customer says, "Hey, we want to order $100,000 of products next week," we can deliver that. You know, and you know, unfortunately, things we can only control, we can control. Hope that helps.

Thank you.

Thank you.

We have a question from Adam Hutt from Leviticus Partners. Your line is open.

One for the road, boys. I'm familiar with a company called Interpace that had a pancreatic cancer test. They pretty much got knocked out by the insurance companies. Stock has been a big wealth destructor. Obviously, the blood cancers, I think, are probably you're able to show much more efficacy and return on the dollar, I think, than a particular pancreas test. Should any of us be losing sleep over the insurance monster? That's a bit of a bugaboo this quarter.

Thank you, Adam. Yeah. You know, I don't know if it's losing sleep, but it's always a concern because you know, they're the payers and they're the ones who ultimately decide. You know, it's not a usual kind of supply and demand model. It's really the payers kind of determine what the revenue or what the payments are gonna be. Having said that, all of our products and certainly all of our services use established CPT codes. I'm not familiar with Interpace, but you know, if there's a company that doesn't have an established CPT code or it's a new code that was just assigned, there's a lot of uncertainty around that, and I don't really think that exists.

You know, our tests, and the codes we use are long ago established codes, and they're not going anywhere. They're supported by, you know, thousands of pages of clinical validated data. I think in that sense, you know, are there gonna be rate fluctuations like we saw? Sure. We as a company have to respond by being more efficient to keep that margin. We're doing exactly that. I don't think it's gonna be a situation where they're gonna say, "You know what? We're not testing for [inaudible] not paying for that anymore." I don't think that's gonna happen. I think relatively speaking, we're okay.

Do you have any restitution against the rate at which they try and lower you to? What can you do besides just margin from within?

No.

Can't really sue the insurance companies, can you?

No.

Can you?

No, you can't. No, you can't. That's pretty much it. For the most part, you know, we haven't really seen anything egregious when there's, you know, when there's clinical support data. It's usually relatively stable and you know, this is kind of the first drop that we've seen in 15 years of operating. It's an 8% drop on one of our tests. It's a frequently run test, but it's an 8% drop. I think in general, this is a pretty stable field.

Thank you.

Thank you.

All right. There are no questions at this time. This concludes today's conference. Thank you for attending. You may now disconnect.

Welcome to the Precipio Q4 2025 and year-end shareholder update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectations, forecasts, and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms, or other words or terms of similar meaning.

Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under risk factors in our annual report on Form 10-K for the year ended December 31, 2025, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward-looking statements, speak only to the date they are provided, unless an earlier date is indicated, and we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Now, let me hand the call over to Ilan Danieli, Precipio CEO. Please go ahead.

Good afternoon, and thank you for joining our 2025 fourth quarter and year-end shareholder call. I'd like to thank everyone who submitted questions ahead of time. We will do our best to address them during the call. Before we begin our financial review, and for those of our shareholders that are relatively new to Precipio, I'd like to take a moment to reflect on the impact our work has on patients every day. Behind every diagnostic test we run is a patient waiting for answers, often during one of the most difficult moments of their lives. Our test helps physicians determine the most appropriate treatment options for their patients battling cancer, and those answers must be provided quickly and accurately. While today's discussion will focus primarily on financial performance and operational progress, it's important to remember that these results ultimately represent something that is beyond dollars and cents.

It represents our contribution to helping patients with it, and their families navigate their battle against cancer. Now, let's turn to a review of our performance in 2025. 2025 was a year of financial and strategic inflection. At the beginning of last year, we set out to achieve an important objective for Precipio, transition from a cash using company to a self-sustaining business with positive cash flow. I'm pleased to report that in 2025 we achieved that inflection point. During the year, we also achieved several other important milestones, continued revenue growth, improved gross margin and operational leverage, the exercise of all remaining financial warrants, removing any related overhang, and the completion of the repayment of Change Healthcare loan, allowing the company to move towards a clean balance sheet.

For many years, like most emerging diagnostic companies, we had to manage the business with the constant constraint of conserving capital and extending our runway. That discipline shaped our company into the highly efficient organization that we are today. It also meant that many decisions had to be made with short-term capital preservation in mind. Today, we enter a new phase of the company's development. The discipline remains, but we are now increasingly able to deploy resources towards growth initiatives and long-term value creation. The company's moving from focusing primarily on stabilization to one increasingly centered on growth and execution. During the call, we'll highlight several examples of that shift. Now, let me turn to our financial results for the year. For fiscal year 2025, Precipio delivered $24 million in revenue, representing a 30% increase YoY compared to 2024.

This level of growth reflects the continued expansion, primarily in our Pathology Services division, as well as strengthening demand for our specialized cancer diagnostic services and molecular testing technologies. Equally important, this growth demonstrates the operational leverage embedded in our business model. A large portion of our cost structure, including laboratory infrastructure, scientific personnel, and operational systems, is already in place as a fixed cost. As a result, incremental revenue can be absorbed efficiently without requiring proportional increases in operation costs. Therefore, more dollars can go directly to the bottom line. In other words, revenue growth increasingly translates into improved margins and stronger cash flow. This operational leverage has been a key driver of the improvement in our financial performance throughout the year.

While I'm pleased with the progress we made in 2025, I wanna emphasize that we believe we are still in the early stages of realizing the full financial potential of this model. Let's begin with our Pathology Services division, which continues to serve as the operational and financial backbone of the company. Throughout the year, we experienced strong organic growth in this division, driven by both acquisition of new customers and increased testing volume from existing customers. One of the most encouraging aspects of this growth is that it has been achieved without requiring significant additional capital expenditures or laboratory staffing increases. Our laboratory infrastructure remains well below its maximum capacity, meaning that incremental case volume flows efficiently through the system and contributes directly to the improved margins and cash generation.

Beyond revenue generation, the Pathology Division also provides a unique strategic advantage for Precipio as it relates to our Products Division. Because we operate a full clinical laboratory, we have direct access to incoming patient samples and a real-world testing environment. This allows us to develop, validate, and refine diagnostic products rapidly and efficiently before we introduce them to the market. Few diagnostic companies possess this dual capability of operating both a clinical laboratory and a product development platform under the same roof, and we believe this integrated model provides Precipio with a meaningful competitive advantage. Looking ahead, our objective for the division remains straightforward: continue growing organically while allowing it to serve as a stable, cash-generating foundation for the company. Now, let's turn to the Products Division, which we believe represents the company's greatest long-term opportunity.

First of all, it's important to acknowledge that the Products Division revenues did not grow as expected this year. There are a few reasons for this, and on this call, I'd like to talk about two main causes. First, we experienced several customer operational fluctuations. While we did add new customers during the year, we also had pauses from several other customers due to their internal factors, ranging from machine downtime to lab tech maternity leave. This caused temporary loss of revenues and subsequent fluctuations, which essentially canceled out some of the growth from new customers. The good news is we learned from all these situations, and we implemented additional business continuity measures that are intended to reduce these fluctuations in the future.

For example, as part of our process, when we now onboard a new customer, we may establish at the customer's selection our lab as a backup testing facility to be used if the customer experiences a temporary operational interruption. If activated, our clinical laboratory is then used as the customer's send out lab. This means that if they are down for any reason, the samples get sent to our lab in accordance with the customer's instructions, which helps support continuity of patient testing during those service interruptions. This provides continuous, consistent service to their clinicians, something that's always important to any laboratory, and it provides continuity of revenues to us. The second reason for the lack of substantial growth was the limited commercial team we had in place. We had one senior executive spending part of their time on product sales, plus another junior sales person.

This team proved to be insufficient for the growth we were targeting. At the start of 2024, that's all we could afford. That's an example of the company playing defense. With the shift towards our cash position came a change in the form of now playing offense. Towards the end of 2025, as we saw our business swing to profitability, we focused on strengthening the Products commercial team. In January 2026, we hired an industry veteran, experienced Chief Commercial Officer, plus two seasoned experienced business development officer professionals full-time. We went from barely one person working on the commercial growth of the Products Division to three dedicated, full-time, and experienced team member. This team will focus on both direct sales as well as developing the relationships we need with our distributors to get into tougher to access customers.

I'm confident that with this team, we'll be making a lot of progress. Having said that, during 2025, we saw encouraging progress in this division. Product revenues were impacted by several factors, including the lapse and subsequent return of several customers to full operational volume, the acquisition of new customers, and organic growth from existing customers expanding their test menu by adopting additional HemeScreen and BloodHound panels. We expect to see the impact of all those factors during 2026. One important characteristic that our platform continues to demonstrate is the following. Once laboratories adopt our technology, they tend not only to stay with it, but also expand their usage over time. We also continue strengthening our distributor partnerships, which represent an important pillar of our long-term growth strategy.

Distribution relationships will eventually allow us to reach a significantly larger number of laboratories than we could through direct sales alone, providing more scalable pathway for expanding the adoption of our technology. As many of you know, onboarding a new laboratory customer in the diagnostic industry involves several steps, including validation studies, workflow integration, IT, and regulatory review. These processes can occasionally delay the start of revenue. However, we continue to see a growing pipeline of laboratories progressing through the onboarding process, each representing potentially substantial recurring revenue as they move into full clinical expansion. Now, turning briefly to margins.

Overall gross margin improved year over year from 41% in 2024 to 45% in 2025, primarily driven by higher case volumes in our Pathology Services division, a more favorable case mix towards higher-margin tests, and continued improvement of operational efficiency. In the Products Division, margins were temporarily, in fact, impacted by strategic investments made during the year, including expansion into a larger facility and additional manufacturing in Q3, resulting in gross margins of 30%. However, in Q4, we saw a leap to 90% gross margins for our product. Now, I know this is a surprising number, especially leaping from 30% in the previous quarter. Let me take a moment to explain this operationally.

First of all, as a reminder, historically, we were consistently at around 40%-50% gross margins, and in Q3 we dropped to 30% because of the additional expenses that were burdened into the manufacturing costs. I'd like to treat 50%, the 50% margin number, as our baseline given our current production volume. Here's why Q4 margins jumped to 90%. As part of our production planning in Q4 2025 and looking to Q1 2026, we anticipated two disruptions to our production schedule. The first was downtime due to year-end holidays and staff taking time off. The second was equipment maintenance expected in Q1 of 2026, where our production machines would be down for approximately two to four weeks.

Therefore, in order to ensure we had adequate inventory for our customers, in addition to the scheduled production runs to fulfill orders in Q4, we produced significantly more inventory to cover expected Q1 2026 demand. Keep in mind, when we produce these products, they are intended for sale to our product customers as well as consumed in our own clinical lab. As a result of this larger, more concentrated production run, we inadvertently achieved a much higher margin of 90%. While this was unusually high due to manufacturing circumstances, this is an illustration of the scalability of our products manufacturing capabilities and the impact to margin we can expect to achieve in the Products Division as we scale up. As volumes grow, we expect the division to demonstrate the strong margin profile typical of successful diagnostic product companies. Beyond Financial Performance, 2025 included several important operational and commercial achievements.

I'd like to share a few of them with you. We continued the expansion of the HemeScreen and BloodHound molecular platform. We published an exciting joint academic study with one of the leading cancer centers in the country, Memorial Sloan Kettering Cancer Center in New York, demonstrating the novel clinical value of our BloodHound BCR-ABL product. We presented a poster at the AMP Annual Meeting & Expo, Association for Molecular Pathology, in collaboration with Wayne State University, showcasing the clinical value of our HemeScreen Cytopenia panel. We made improvements in customer onboarding processes, we expanded our manufacturing capacity, and we strengthened the company's financial position through debt repayment. We believe that each of these milestones contributes to building a more scalable and durable business. Moving now to market interaction. In 2025, we also began to interact more with the public markets.

In 2024 and before, we remained relatively silent and didn't really engage with investors. If an investor reached out to us requesting a call with management, we typically politely declined and responded that management is not currently speaking directly with investors. As our story developed and our performance improved, in 2025, we began responding to those inquiries and engaging with investors, both in one-on-one meetings as well as in various public forums and conferences. During 2025, we had more than 50 unique interactions with investors, family offices, institutional funds, and analysts. I believe that while the 300% share price appreciation we saw in 2025 was primarily due to the company's business and financial performance, it's also due to the increased engagement with investors. We plan to continue to engage with the market this year. Looking ahead to 2026, our focus is on growing the products business.

With our new dedicated and experienced product sales team, as well as process improvements we've implemented, we will focus on accelerating the adoption of our HemeScreen and BloodHound products, converting our pipeline of laboratories into active revenue-generating customers, and expanding the number of institutions utilizing our platform. We expect to see continued growth in the Pathology Services side of the business as well, further generating cash that will be reinvested primarily into the Products business growth. One example of an opportunity for us is an AML or Acute Myeloid Leukemia testing, particularly where most hospital laboratories currently rely on external reference testing and where turnaround time of testing results can have a direct critical impact on patient lives. Today, most hospital laboratories across the country do not perform AML testing internally and instead send the patient samples to external reference laboratories.

For AML testing, these reference labs typically deliver results to the clinician in seven to 10 days, and this is despite the AML guidelines requiring results delivered within five days. With several targeted therapies tied to specific mutations tested, receiving immediate results is a critical life and death decision. The problem is there is a severe mismatch between the clinical situation facing the doctors and their patients and the diagnostic options available in to meet most of these situations. Therefore, we see an unmet need for testing workflows that can better support timely clinician's decision-making. By using the combined strengths of our Pathology Services division and our BloodHound AML assay, we will be launching a service that combines rapid molecular testing. When I say rapid, I mean next day results, followed up by a comprehensive analysis five days later.

We believe this service could further differentiate our platform and expand both our services opportunity as well as introduce laboratories to the products we offer. This is just one example of the superior service our technology enables us to provide. Further details will be announced as we launch this offering. We see significant opportunities to expand the share of our Products Division within an estimated $500 million addressable market annually in the U.S. As we execute on our strategy over the next three to five years, we expect the company's revenue mix to move from its current approximate 90/10 weighting towards Pathology Services to a more balanced revenue mix between Pathology Services and Products Division. In summary, while there is still work ahead, we believe the foundation we've built is strong and the opportunities ahead of us significant.

In 2026, our focus will be on growth execution, commercial momentum, increased market share, and ensuring that our progress is communicated clearly to the market. I'd like to thank our employees, customers, partners, and shareholders for their continued support and trust. We look forward to updating you again next quarter as we continue executing on our strategy and building long-term value for our shareholders. Thank you and have a great evening.

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.

Welcome to the Precipio Q2 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that this conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon current expectations, forecasts and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under Risk Factors in our annual report on Form 10-K for the year ended December 31, 2024, which is on file with the Securities and Exchange Commission as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward-looking statements speak only to the date they are provided, and we do not undertake any obligations to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Now let me hand the call over to Ilan Danieli, Precipio's CEO. Please go ahead.

Good afternoon, and thank you all for joining us today to review Precipio's financial and operational results for the second quarter of 2025. I appreciate the questions that were sent in, and I'll do my best to address them. On this call, I'd like to give a bit of color around each of our divisions, the Pathology Services division and our Products division. I'll discuss some of the changes and improvements we're constantly making to the business and lastly, discuss the company's financial status and where we see things going forward. Q2 marked another strong quarter of positive momentum with continued revenue growth, improved margin and progress towards breakeven. Overall, our Pathology Services business is growing at a healthy clip and at an annualized growth rate of about 70%. Our Products revenue grew by 23% from the previous quarter, which represents almost 100% annualized growth rate. This reflects recovery from last year's temporary decline, which was primarily driven by a few customer disruptions. Later on this call, I'll share the steps we're taking to mitigate the impact of future such disruptions and strengthen the stability of our revenue base. Looking briefly at Q3, we have a strong pipeline of new customers in various onboarding stages, and we expect Q3 to show continued growth. Some of these customers were introduced to our distributors, which is a very good step towards scaling up our market penetration. More of that later on this call as well. In terms of gross margin and contribution to the bottom line cash flow, although we had a slight decline in product gross margin, which will likely be reversed next quarter, overall company gross margins improved from 39% to 43%. From a cash perspective, certain strategic investments were made this quarter, such as the expansion of our laboratory space and acquiring key equipment. Those investments have only modestly impacted our near-term trajectory towards breakeven. They are relatively minor in the context of our overall financial position and operational performance. Management remains confident in the strength of our business and continues to believe that we are well positioned to reach breakeven without the need for additional capital. We remain on track to achieve that milestone in 2025. Now turning to a more detailed breakdown of our divisional operation, beginning with Pathology Services. The Pathology Services division continued to deliver consistent revenue and to generate cash for the company. Our sales team continues to bring in new customers and the lab executes on the incoming volume to provide outstanding service to our customers. While outside the scope of Q2, I would like to briefly highlight that in July, we had a new record, exceeding $2 million in Pathology Services revenue in a single month. While these figures are unaudited and fall within Q3, we hope they reflect the continued momentum we're seeing as we enter the second half of the year. Pathology is a business that's driven by patient needs, and as such, they fluctuate daily. So sometimes it's hard to predict whether this was just a really busy month with unusually high volume or that this is a level that we can anticipate going forward. However, as this was not our first record to break, I'm quite confident it's not our last either. Margins continue to increase with scale efficiencies, and our models show us leveling off at around 50% gross margins sometime in 2026. Cash receipts are solid with a high collection rate and low DSO, which means that this division is self-supportive and cash generating. But more importantly, as we've discussed in the past, this division also generates samples for our Products division. These samples are critical to the ongoing development of current and new products we have in the pipeline and ensuring we're able to adequately support our customers. And with that, let's segue to the Products division. As we discussed previously, we had a few ups and downs with our customers due to various operational challenges they faced. Machines went down and required repair, lab techs left and needed to be replaced. These issues caused revenue fluctuation over the past year and resulting in a drop in revenue from some of those customers. Therefore, despite us adding new customers, those revenue drops somewhat masked our current growth of new business. I'm pleased to report that as of this quarter, those issues are behind us, and those customers are back on track with revenue starting to build back up. Alongside new customers coming on board, we expect to see continued customer and revenue growth. One of the things we realized when these customers had to pause their operations is that not only did it obviously impact our revenue, but it also impacted the service level our customer laboratory provided and the doctors has gotten used to. The faster turnaround time that our customer laboratories can deliver, the improved coverage, the increased accuracy, all those are elements that doctors quickly get used to, and they don't like it when those elements get taken away. Therefore, as part of our broader commitment to customer support and service continuity, we implemented an optional send-out continuity program. When we onboard new customers, we offer them the opportunity to designate our clinical laboratory as a backup testing site for our test in case of unexpected service disruptions, such as equipment proven downtime or other problems that can cause them to pause their testing. This arrangement is designed to ensure uninterrupted patient testing and care delivered by our customers to their patients. In our lab, we use the same validated assays, maintain consistent quality and provide rapid turnaround time. Participation in this program is not tied to any purchasing requirements or commercial commitments. This approach ensures our customers can continuously provide consistent service without interruption for these tests, whether they run them in-house in their lab or temporary send patient samples to us. From our perspective, it also enables continuity in revenue when these situations occur, temporarily shifting from product-based revenue to service-based revenue within our Pathology Services division during those periods when customers are unable to run tests in-house. This is a key differentiator for us. Unlike most manufacturers, we operate our own clinical lab, and we use our products clinically on a daily basis just like our customers do. This enables us to serve as a backup testing facility for customers during service disruptions, helping them maintain consistent, high-quality results for their patients and their physicians. The second point I want to make is that we're starting to see an increase in the pipeline generated by our distributors, and this is something we've been working hard to achieve. Up until recently, the vast majority of revenue was from direct sales generated internally by our product commercial team. And while it's great to have direct customers, we've always believed that the way to scale up the business is through our distributors. This is because the toughest part of the sales process is getting to the right person within the customer organization. Our distributors have had years-long relationships with these laboratories. And so the theory is that we can leverage those relationships to accelerate customer penetration by rapidly getting in front of those decision-makers. Now as we've seen, translating that theory into practice is not as simple. Distributor reps have thousands of other products in their bag. And so until we prove ourselves, we have to compete for the reps' mindshare. Additionally, most reps are risk averse and any new customer and new product represents a risk when bringing them into an existing valued customer. So how do we overcome those hurdles? Like in any business, the first few customers are the toughest ones to win. But once we successfully onboard them, then demonstrate that the customer gains clinical and financial value as well as the sales rep making commission from our products, once that happens, the story spreads and other reps gain comfort that our product is going to perform well and make them and their customers' money. Over the next couple of quarters, we're going to build a few of those success stories with several of our distributors and make sure those stories are spread throughout their respective organizations. More to come on that as we continue to make progress with our distributors. Now let's turn to a few comments related to the company finances. First, I'd like to address the recent warrant conversion, which although happened in Q3, we received many questions about it. So I wanted to make sure everyone is clear on what we did and why. Two years ago, back in 2023, the company did a financing with warrants attached to it. Those warrants had an exercise price of approximately $12. And so when the stock price exceeded $12, the investor called us up to exercise the warrants. The investor held approximately 300,000 warrants, which meant that under normal warrant exercise procedures, the investor would have paid the company approximately $3.6 million. That's 300,000 shares -- sorry, 300,000 warrants times $12 and received 300,000 shares, which they would likely turn around and sell on the open market as long as the share price remains above $12, thereby making a margin on those warrants. Issuing the shares would have resulted in a substantial increase in the total share count, potentially placing downward pressure on the stock price. From a shareholder value perspective, we determined that such dilution was not in the best interest of our shareholders. Moreover, given the company's current financial position, management concluded the potential capital raise, approximately $3.6 million, was not essential at this time, particularly at the cost of significant equity dilution. Following careful consideration, we engaged with the investor and reached an agreement to structure the warrant exercise in a way that balanced capital inflow with dilution control. Under the terms of the agreement, approximately 1/3 of the warrants or around 100,000 were exercised in a standard manner, generating approximately $1.2 million in cash to the company in exchange for 100,000 shares. The remaining 2/3 of approximately 200,000 warrants are exercised on a cashless basis, resulting in no additional cash to the company, but also a significantly lower number of shares issued to the investor. This structure was intentionally designed to reduce the number of new shares entering the market, thereby minimizing dilution and any potential downward pressure to our existing share price. It also reflects our commitment to supporting our positive momentum we've seen in our share price over the past several months while responding -- responsibly managing our capital structure, which brings me to our next point of the discussion and probably the question that we were most asked, why did the stock triple in the last quarter? Although my answer is nothing more than speculation, we don't really know what drives investor and market behavior. I think there are 2 key driving factors I'd like to share with you. The first is company performance. This quarter will be the third consecutive quarter of solid revenue growth, improved margins and reduced needs of cash. All these put us on a clear path to breakeven and subsequently to profitability, which I think makes us a very attractive company, especially relative to our revenues, valuation and market cap. Second, we've begun to tell our story. Our company usually receives at least 10 inquiries a week from banks, funds, family offices and individual investors who want to learn more about the company. Up until last quarter, we would respond politely and say we are not conducting such conversations at this time. For the last 2 years, we intentionally remained in stealth mode, kept our head down and focused on growing the business. This quarter, when we finally began to develop a good track record we could point to, we began taking those calls and speaking with various investors to tell our story. And so I think our situation is gradually changing from a virtually unknown story to one that more people are starting to follow. And I think that following has translated into more interest in our company and an increase in demand relative to the limited supply of our shares in the open market. We plan to continue this approach of gradually coming out to the market and telling our story. Our performance continues to improve and so will our story. And alongside that, we'll engage in more public company activities such as participating in investor conferences and others. This is an exciting time to be part of our company. We recently celebrated 14 years, and it's certainly been quite a climb. We have so much more to accomplish, but we also have come a long way, and I think this is a pivotal time for Precipio. With that, I'd like to thank you for your ongoing support and looking forward to our next shareholder call. Have a nice weekend.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.